Genotype/phenotype studies in patients with hoFH indicated the potential for efficacy in those with complete deficiency of LDLR following less than complete genetic reconstitution from gene therapy [9], [10], [33]. This evidence concerns the gene LDLR and homozygous familial hypercholesterolemia.